TEVA PHARMACEUTICAL INDUSTRIES LIMITED Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $724.00 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2020-05-07
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2020-03-31 was $724.00M, a 48.06% increase year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2019-12-31 was $476.00M, a 88.45% decline year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2019-03-31 was $489.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2018-12-31 was $4.12B.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2019 was $1.78B, a 68.37% decline from fiscal 2018.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $5.62B, a 73.08% decline from fiscal 2017.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $20.88B.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|---|---|
| 2020-03-31 | $724.00M 10-Q · filed 2020-05-07 | $1.20B derived: sum of 2 quarters · filed 2020-05-07 | |||
| 2019-12-31 | $476.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $1.78B 10-K · filed 2020-02-21 | |||
| 2019-09-30 | $1.30B 10-Q · filed 2019-11-07 | ||||
| 2019-03-31 | $489.00M 10-Q · filed 2020-05-07 | $4.61B derived: sum of 2 quarters · filed 2020-05-07 | |||
| 2018-12-31 | $4.12B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $5.62B 10-K · filed 2020-02-21 | |||
| 2018-09-30 | $1.50B 10-Q · filed 2019-11-07 | ||||
| 2017-12-31 | $20.88B 10-K · filed 2020-02-21 | ||||
| 2015-12-31 | $108.00M 20-F · filed 2016-02-11 | ||||
| 2014-12-31 | $64.00M derived: 20-F 12 month − 6-K 9 month · filed 2016-02-11 | $166.00M 20-F · filed 2016-02-11 | $108.00M 20-F · filed 2015-02-09 | ||
| 2014-09-30 | $102.00M 6-K · filed 2014-10-30 | ||||
| 2013-12-31 | $526.00M derived: 20-F 12 month − 6-K 9 month · filed 2016-02-11 | $625.00M 20-F · filed 2016-02-11 | $166.00M 20-F · filed 2014-02-10 | ||
| 2013-09-30 | $99.00M 6-K · filed 2013-10-31 | ||||
| 2012-12-31 | $625.00M 20-F · filed 2015-02-09 |